A 24‐weeks real‐world experience of dupilumab in adolescents with moderate‐to‐severe atopic dermatitis-Reference-Cited by-同舟云学术

A 24‐weeks real‐world experience of dupilumab in adolescents with moderate‐to‐severe atopic dermatitis

Published:2022-05-22 Issue:8 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Napolitano Maddalena¹^ORCID,Fabbrocini Gabriella²^ORCID,Potestio Luca²^ORCID,Fontanella Giuseppina²,Picone Vincenzo²^ORCID,Bennardo Luigi³^ORCID,Scalvenzi Massimiliano²,Patruno Cataldo³

Affiliation:

1. Department of Medicine and Health Sciences “Vincenzo Tiberio” University of Molise Campobasso Italy

2. Section of Dermatology – Department of Clinical Medicine and Surgery University of Naples Federico II Naples Italy

3. Department of Health Sciences University Magna Graecia of Catanzaro Catanzaro Italy

Publisher

Hindawi Limited

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15588

Reference19 articles.

1. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis

2. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study

3. Eczema across the World: The Missing Piece of the Jigsaw Revealed

4. https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent

5. Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A risk-scoring system to predict dupilumab-associated ocular surface disease in patients with atopic dermatitis;Frontiers in Pharmacology;2024-08-01

2. Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations;Journal of Asthma and Allergy;2024-08

3. Bridging the Gap: Comparing Patient-Clinician Views on Treatment Goals and Communication in the Management of Atopic Dermatitis Within the Asia–Pacific Region;Dermatology and Therapy;2024-07-15

4. Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond;Expert Opinion on Biological Therapy;2024-06-02

5. Interleukin antagonists for atopic dermatitis: a new era of therapy;Expert Opinion on Investigational Drugs;2024-06-02